4D Molecular Therapeutics stock rises on $85 million Otsuka deal By Investing.com
Update: 2025-10-31
Description
4DMT, a late-stage biotech company, has secured a major partnership with Otsuka Pharmaceutical to develop and market its 4D-150 therapy for eye diseases in the Asia-Pacific region. The deal includes an upfront payment of $85 million, potential milestones of up to $336 million, and double-digit royalties. 4DMT retains global control outside the Asia-Pacific market, with both companies aiming to bring this innovative therapy to patients suffering from vision loss due to retinal diseases.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
